Fatty acid synthase inhibitors

A compound according to Formula (I),

• wherein
• R1 is phenyl, 5- or 6-membered heteroaryl, naphthyl, 9- or 10-membered heterocyclyl;
• wherein said phenyl, 5- or 6-membered heteroaryl, naphthyl, 9- or 10-membered heterocyclyl, is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of:
• optionally substituted C1-C6alkyl;
• —CF3, C3-C7cycloalkyl, —C(═O)C1-C4alkyl, —C1-C6alkylC3-C7cycloalkyl, —C(═O)C3-C7cycloalkyl, —C(═O)(phenyl), —C(═O)OC1-C4alkyl, —C(═O)OH, —C(═O)NR5R6, —O(C2-C4alkyl)NR5R6, phenyl, —SO2C1-C4alkyl, —SO2NR5R6, cyano, oxo, hydroxyl, halogen, C1-C4alkoxy, C3-C7cycloalkylC1-C4alkoxy, hydroxyC1-C4alkyl-, C1-C4alkoxyC1-C4alkyl-, —OCF3, —NR5R6, R5R6NC1-C4alkyl-, —NR7C(═O)C1-C4alkyl, —NR7C(═O)NR5R6, —NR7SO2C1-C4alkyl, —NR7SO2NR5R6 and R9;
• R5 is selected from the group consisting of hydrogen, C1-C4alkyl, C3-C7cycloalkyl, —C1-C3alkylC3-C7cycloalkyl, phenyl, and —C1-C3alkylphenyl;
• R6 is hydrogen, C1-C4alkyl, C3-C7cycloalkyl, or —C1-C3alkylC3-C7cycloalkyl;
• or R5 and R6 taken together with the nitrogen to which they are attached represent a 3- to 7-membered saturated ring optionally containing one other heteroatom which is oxygen, nitrogen, or sulfur, which is optionally substituted 1 or 2 times independently by oxo or C1-C4alkyl;
• R7 is hydrogen or methyl;
• R9 is a 5- or 6-membered heteroaryl ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen, and sulfur, which is optionally substituted with 1 or 2 substituents selected from halogen, C1-C4alkyl, CF3, C1-C4alkoxy, and —NR5R6;
• each R2 is selected from the group consisting of halogen, C1-C6alkyl, hydroxyl, and C1-C4alkoxy;
• R3 is selected from the group consisting of:
• C1-C6alkyl, C3-C7cycloalkyl, hydroxyC1-C6alky-, and C4-C6heterocycloalkyl, wherein said C1-C6alkyl, C3-C7cycloalkyl, hydroxyC1-C6alky-, and C4-C6heterocycloalkyl is optionally substituted with from 1 to 4 substituents independently selected from the group consisting of:
• halogen, C1-C6alkyl, —CF3, C3-C7cycloalkyl, —C(═O)C1-C4alkyl, —C(═O)C3-C7cycloalkyl, —C(═O)(phenyl), —C(═O)OH, —C(═O)OC1-C4alkyl, —C(═O)NR5R6, phenyl, —SO2C1-C4alkyl, —SO2NR5R6, cyano, oxo, hydroxyl, hydroxyC1-C6alky-, C1-C4alkoxy, C3-C7cycloalkoxy, C1-C4alkoxyC1-C4alkyl-, —OCF3, —NR5R6, R5R6NC1-C4alkyl-, —NHC(O)C1-C4alkyl, —NHCONR5R6, —NHSO2C1-C4alkyl, and —NHSO2NR5R6;
• each R4 and R4a is independently selected from hydrogen, halogen, C1-C6alkyl, hydroxyl, or C1-C6alkoxy;
• wherein R8 and R8a are independently selected from hydrogen, deuterium, cyano, optionally substituted C1-C4alkyl, —C1-C4alkylhydroxy, C1-C6alkoxy, —C1-C4alkyl(═O)OH, —C1-C4alkyl(═O)OC1-C4alkyl, —C1-C4alkyl(═O)NR5R6, —C1-C4alkyl(═O)C1-C4alkyl, —C1-C4alkylSO2C1-C4alkyl, —SO2C1-C4alkyl, —C1-C4alkylSO2NR5R6, —SO2NR5R6, —C1-C4alkylNR5R6, —C1-C4alkylNR5SO2C1-C4alkyl, —C1-C4alkylNR5SO2NR5R6, —C1-C4alkylNR5C(═O)C1-C4alkyl, —C1-C4alkylNR5C(═O)NR5R6, C1-C4alkyl(═O)NR5OR6, triazolyl, and R9 wherein any C1-C4alkyl and C1-C6alkoxy moiety is optionally substituted with from 1 to 6 substituents independently selected from the group of:
• halogen, C1-C4alkyl, —CF3, C3-C7cycloalkyl, —C(═O)C1-C4alkyl, —C(═O)C3-C7cycloalkyl, —C(═O)phenyl, —C1-C4alkylC(═O)OH, C(═O)OH, —C(═O)OC1-C4alkyl, —CONR5R6, phenyl, —SO2C1-C4alkyl, —SO2NR5R6, cyano, oxo, hydroxyl, C1-C4alkoxy, C3-C7cycloalkoxy, hydroxyC1-C4alkyl-, C1-C4alkoxyC1-C4alkyl-, —OCF3, —NR5R6, R5R6NC1-C4alkyl-, —NR7C(O)C1-C4alkyl, —NR7CONR5R6, —NR7SO2C1-C4alkyl, —NR7SO2NR5R6, and R9, wherein when R8 is hydrogen R8a is not hydrogen or deuterium and wherein when R8 is deuterium R8a is not hydrogen or deuterium;
• or R8 and R8a taken together with the carbon to which they are attached represent a 3- to 6-membered saturated ring optionally containing one or two heteroatoms selected from oxygen, nitrogen, and sulfur, which is optionally substituted 1 to 3 times by oxo, C1-C4alkyl, halogen, C1-C4alkylhydroxy, C1-C4alkoxy, or —NR5R6;
• m is 0, 1, 2 or 3;
• Y is C or N;
• or a pharmaceutically acceptable salt thereof.